GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 328
- Registration Number
- NCT00880399
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants
Phase 3
Completed
- Conditions
- DiphtheriaHepatitis BPoliomyelitisTetanusAcellular Pertussis
- Interventions
- Biological: Pediarix TM, Infanrix penta TMBiological: Hiberix TM
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00879827
Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV/Hib Vaccine
Phase 3
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: DTPa-IPV/Hib vaccineBiological: DTPa-HBV-IPV/Hib vaccineBiological: EngerixTM-B
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 140
- Registration Number
- NCT00880477
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
Phase 3
Completed
- Conditions
- Papillomavirus VaccinesInfections, Papillomavirus
- Interventions
- Procedure: Blood sampling
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 632
- Registration Number
- NCT00877877
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
Nutrition, Physical Performance & Fitness in Indian School Children
Phase 4
Completed
- Conditions
- Physical FitnessNutritional Status
- Interventions
- Other: PlaceboOther: Nutritional supplement
- First Posted Date
- 2009-04-06
- Last Posted Date
- 2018-03-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00876018
- Locations
- 🇮🇳
GSK Investigational Site, Bangalore, Karnataka, India
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 76
- Registration Number
- NCT00875446
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00875784
- Locations
- 🇺🇸
GSK Investigational Site, Tacoma, Washington, United States
Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™
Phase 4
Completed
- Conditions
- Hepatitis AHepatitis B
- Interventions
- Procedure: Blood samplingBiological: Additional challenge dose
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 210
- Registration Number
- NCT00875485
- Locations
- 🇨🇿
GSK Investigational Site, Hradec Kralove, Czechia
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: Health Insurance Database
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 390659
- Registration Number
- NCT00875641
- Locations
- 🇺🇸
GSK Investigational Site, Waltham, Massachusetts, United States
Tafenoquine/Chloroquine DDI Study
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2017-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT00871156
- Locations
- 🇺🇸
GSK Investigational Site, Buffalo, New York, United States
© Copyright 2025. All Rights Reserved by MedPath